GlassScriptPhysician profile
Dirk W Snyder
NPI 1679675342
$3,846.08
in general payments reported to CMS, 2019-2025
40 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $418 · 2021: $512 · 2022: $652 · 2023: $361 · 2024: $842 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.90 |
| Education | $249.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $638.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $632.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $304.23 | 2021-2025 | Alinity M, Freestyle Libre 3 |
| Abbvie INC. | $260.80 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $238.64 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $230.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $208.91 | 2019-2023 | |
| Glaxosmithkline, LLC. | $114.39 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $97.18 | 2020-2024 | Repatha, Otezla, Tavneos |
| Sanofi-Aventis U.S. LLC | $92.34 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $86.32 | 2024-2025 | Nuzyra |
| Harmony Biosciences LLC | $84.28 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $64.72 | 2019-2021 | |
| Smith+Nephew, INC. | $62.23 | 2019-2024 | Collagenase Santyl |
| Merck Sharp & Dohme LLC | $57.44 | 2021-2023 | Dificid, Recarbrio, Zerbaxa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dirk Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.